Salarius jumps after completing merger with Decoy Therapeutics
13/11/2025 14:38
** Shares of drug developer Salarius Pharmaceuticals SLRX.O rise 17.3% to $1.22 in early trading ** Co and Decoy Therapeutics complete their merger, combining resources to accelerate development of peptide-based drugs for serious diseases - SLRX ** The merged co is renamed Decoy Therapeutics and focuses on advancing Decoy's pipeline, which includes treatments for respiratory infections and gastrointestinal cancers, co says ** SLRX says Frederick "Rick" Pierce, Decoy's co-founder, serves as chief executive officer ** Decoy's technology uses artificial intelligence and rapid manufacturing techniques to design and produce drug candidates quickly - SLRX ** Decoy secures funding from institutional investors and programs run by Massachusetts Life Sciences, Google, NVIDIA, and Johnson & Johnson ** Including session's move, stock down ~94% YTD (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))